source
- Sanofi presents detailed asthma trial data while AstraZeneca reports positive COPD results at ERS 2026At the European Respiratory Society meeting in Barcelona, Sanofi disclosed detailed findings from its asthma trial, building on earlier indications of efficacy. The data highlighted specific endpo…
- Roivant's mosliciguat shows strong Phase 2 results, advancing to Phase 3 for PH-ILDMosliciguat, the pulmonary hypertension candidate from Roivant Sciences subsidiary Pulmovant, cut pulmonary vascular resistance by more than 56% in a Phase 2 trial of patients with PH‑ILD, surpassi…